Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

NCT07314619 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer (PROC)

Interventions

DRUG: Sacituzumab Tirumotecan Combined with Bevacizumab

Sponsor

The First Affiliated Hospital of Zhengzhou University